<DOC>
	<DOCNO>NCT02532634</DOCNO>
	<brief_summary>The purpose study compare anti-emetic effect ramosetron plus aprepitant dexamethasone palonosetron plus aprepitant dexamethasone patient receive highly emetogenic chemotherapy .</brief_summary>
	<brief_title>Ramosetron , Aprepitant , Dexamethasone Versus Palonosetron , Aprepitant , Dexamethasone</brief_title>
	<detailed_description>Currently , palonosetron clinically preferred antiemetic Chemotherapy-induced nausea vomiting ( CINV ) .However best 5-hydroxytryptamine 3 receptor ( 5-HT3R ) antagonist use triple drug combination high emetogenic chemotherapy ( HEC ) yet determine randomize trial . Previous anti-emetic guideline state anti-emetic activity 5-HT3R antagonist similar equivalent dos . Based meta-analysis various 5-HT3R antagonist double regimen , NCCN guideline suggest palonosetron prefer 5-HT3R antagonist triple antiemetic drug combination . But Asia , RAD one popular treatment HEC-treated cancer patient . However , lack clinical study preclude recommendation RAD standard regimen HEC-induced CINV . In two previous study conduct Korea , RAD regimen show significant efficacy prevention CINV comparable efficacy report study evaluate PAD regimen . If efficacy RAD regimen evidently proven kind randomized multicenter-trial , RAD regimen recommend standard regimen HEC-induced CINV .</detailed_description>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Ramosetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<criteria>The patient 's age ≥ 19 year old Histologically cytologically confirm solid tumor Patients diagnose malignancy treat highly emetogenic chemotherapeutic agent ( NCCN guideline v2.0 , 2014 antiemesis ) . ( Cisplatin dosage 50mg/m2 , combination therapy available chemotherapeutic agent include lymphoma ) Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Available oral administration study drug Adequate organ function follow : 1 ) Hematologic white blood cell count ( WBC ) ≥ 3000 microliter ( microL ) Neutrophil≥ 1500 micro/L , Platelet ≥ 100,000/microL ; 2 ) Serum Creatinine ≤ 1.5 time upper limit normal ; 3 ) Hepatic function Total bilirubin , AST , ALT ≤2.5 time upper limit normal , ALP ≤ 2 time upper limit normal ( except ALP increase due bone metastasis Patients normal range serum K , Mg hold serum Ca low limit normal range Patients must sign informed consent indicate aware investigational nature study keep policy hospital Patients severe Hypertension , severe Heart disease , congenital long QT syndrome , bradyarrhythmia severe kidney disease ( serum creatinine≥3㎎/㎗ ) , liver disease ( AST , ALT ≥ 2.5 time upper normal range , ALP ≥ 2 time upper normal range ) Patients GI obstruction , active gastric ulcer disease could provoke nausea vomit Patients nausea vomit within 1 week chemotherapy Patients take steroid , antiemetic , antipsychotic agent include benzodiazepine , pimozide , terfenadine , astemizole , cisapride , rifampin , carbamazepine , phenytoin , ketoconazole , itraconazole , nefazodone , troleandomycin , clarithromycin , ritonavir nelfinavir , selective serotonin reuptake inhibitor , serotoninnorepinephrine reuptake inhibitor treatment diseases Patients brain tumor , brain metastasis seizure Patients receive chemotherapy within 6 month enrollment Patients need radiation therapy study period receive radiation therapy within 2 week chemotherapy Patients know allergy severe side effect study drug ( 5HT3 antagonist aprepitant ) Pregnant lactate woman , woman wish become pregnant Patients drug abuse , mental disease difficult communicate investigator Others investigator judge inappropriate subject study</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>ramosetron</keyword>
	<keyword>palonosetron</keyword>
	<keyword>chemotherapy induce nausea vomiting</keyword>
</DOC>